Fox Run Management L.L.C. Acquires 7,654 Shares of Zoetis Inc. (NYSE:ZTS)

Fox Run Management L.L.C. raised its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 512.3% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 9,148 shares of the company’s stock after purchasing an additional 7,654 shares during the period. Fox Run Management L.L.C.’s holdings in Zoetis were worth $1,490,000 as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in the business. Atlantic Edge Private Wealth Management LLC raised its stake in Zoetis by 482.8% during the fourth quarter. Atlantic Edge Private Wealth Management LLC now owns 169 shares of the company’s stock valued at $28,000 after buying an additional 140 shares during the last quarter. Rakuten Securities Inc. increased its holdings in shares of Zoetis by 5,533.3% during the fourth quarter. Rakuten Securities Inc. now owns 169 shares of the company’s stock valued at $28,000 after acquiring an additional 166 shares in the last quarter. Darwin Wealth Management LLC purchased a new position in shares of Zoetis in the 3rd quarter worth about $31,000. Dunhill Financial LLC boosted its stake in Zoetis by 80.6% in the 3rd quarter. Dunhill Financial LLC now owns 168 shares of the company’s stock worth $33,000 after purchasing an additional 75 shares in the last quarter. Finally, Asset Planning Inc purchased a new stake in Zoetis during the 4th quarter valued at about $58,000. 92.80% of the stock is currently owned by hedge funds and other institutional investors.

Zoetis Stock Down 0.2 %

ZTS stock opened at $162.86 on Friday. The business’s 50-day moving average is $166.76 and its two-hundred day moving average is $175.52. The company has a market cap of $72.93 billion, a price-to-earnings ratio of 29.77, a P/E/G ratio of 2.78 and a beta of 0.94. Zoetis Inc. has a fifty-two week low of $144.80 and a fifty-two week high of $200.33. The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.08 and a current ratio of 1.75.

Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Thursday, February 13th. The company reported $1.40 earnings per share for the quarter, topping the consensus estimate of $1.37 by $0.03. The firm had revenue of $2.32 billion for the quarter, compared to analysts’ expectations of $2.30 billion. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. As a group, analysts forecast that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 3rd. Stockholders of record on Monday, April 21st will be given a dividend of $0.50 per share. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.23%. The ex-dividend date of this dividend is Monday, April 21st. Zoetis’s payout ratio is 36.56%.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on ZTS shares. StockNews.com upgraded shares of Zoetis from a “hold” rating to a “buy” rating in a research note on Friday, March 7th. Piper Sandler upped their price objective on Zoetis from $200.00 to $205.00 and gave the company an “overweight” rating in a research report on Thursday, February 27th. Leerink Partners began coverage on Zoetis in a research note on Monday, December 2nd. They set an “outperform” rating and a $215.00 target price on the stock. Barclays upped their price target on Zoetis from $242.00 to $244.00 and gave the company an “overweight” rating in a report on Friday, February 14th. Finally, UBS Group initiated coverage on Zoetis in a report on Monday, December 9th. They issued a “neutral” rating and a $196.00 price objective for the company. One analyst has rated the stock with a hold rating, ten have given a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $215.90.

Insider Transactions at Zoetis

In related news, EVP Roxanne Lagano sold 326 shares of the business’s stock in a transaction that occurred on Tuesday, February 11th. The stock was sold at an average price of $171.18, for a total transaction of $55,804.68. Following the completion of the transaction, the executive vice president now directly owns 16,107 shares in the company, valued at approximately $2,757,196.26. The trade was a 1.98 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Willie M. Reed sold 1,210 shares of the firm’s stock in a transaction that occurred on Tuesday, March 11th. The stock was sold at an average price of $166.14, for a total transaction of $201,029.40. Following the sale, the director now owns 11,245 shares in the company, valued at approximately $1,868,244.30. The trade was a 9.71 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 1,862 shares of company stock worth $312,254 in the last three months. Corporate insiders own 0.16% of the company’s stock.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.